Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Earl, Julie ^a   Garcia Nieto, Sandra ^a   Martinez Avila, Jose Carlos ^b   Montans, José ^a   Sanjuanbenito, Alfonso ^a   Rodríguez Garrote, Mercedes ^a   Lisa, Eduardo ^a   Mendía, Elena ^a   Lobo, Eduardo ^a   Malats, Núria ^b   Carrato, Alfredo ^a   Guillen Ponce, Carmen ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Circulating Free DNA; Circulating Tumor Cells; KRAS mutation; PDAC; Prognostic Marker

Indexed keywords

CD45 ANTIGEN; CIRCULATING FREE DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; MALE; METASTASIS; MINIMALLY INVASIVE PROCEDURE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PILOT STUDY; POLYMERASE CHAIN REACTION; BLOOD; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PHYSIOLOGY; SURVIVAL RATE; TRENDS; TUMOR EMBOLISM;

AGED; BIOMARKERS, TUMOR; COHORT STUDIES; DNA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE;

EID: 84946485944     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1779-7     Document Type: Article

References (26)

1. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Postgrad Med J. 2008;84(995):478-97.
2. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836-47.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17.
4. Buxbaum JL, Eloubeidi MA. Molecular and clinical markers of pancreas cancer. JOP. 2010;11(6):536-44.
5. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266-70.
6. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193-8.
7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-91.
8. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-9.
9. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27(20):3303-11.
10. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556-63.
11. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg. 2008;15(2):189-95.
12. Bidard FC, Huguet F, Louvet C, Mineur L, Bouche O, Chibaudel B, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Annals Oncol. 2013;24(8):2057-61.
13. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106(3):508-16.
14. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426-37.
15. Lee YJ, Yoon KA, Han JY, Kim HT, Yun T, Lee GK, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res. 2011;17(15):5179-87.
16. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177-85.
17. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945-950.
18. Team RDC. R: A language and environment for statistical computing. 2008.
19. Inc S: SPSS Statistics for Windows, Version 17.0. Chicago. Released 2008.
20. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Annals Oncol. 2008;19(5):935-8.
21. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Annals Oncol. 2010;21(5):1006-12.
22. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12(21):6403-9.
23. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624-33.
24. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and Dissemination Precede Pancreatic Tumor Formation. Cell. 2012;148(1-2):349-61.
25. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 2011;105(9):1338-41.
26. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci TranslMed. 2014;6(224):224ra224.